Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML) - Leukemia
- ️Sonneveld, P
- ️Thu May 02 2002
References
Van den Heuvel-Eibrink MM, Sonneveld P, Pieters R . The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia Int J Clin Pharmacol Ther 2000 38: 94–110
Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D . Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis Blood 1992 79: 473–476
Del Poeta G, Stasi R, Venditti A, Suppo G, Aronica G, Bruno A, Masi M, Tabilio A, Papa G . Prognostic value of cell marker analysis in de novo acute myeloid leukemia Leukemia 1994 8: 388–394
Sievers EL, Smith FO, Woods WG, Lee JW, Bleyer WA, Willman CL, Bernstein ID . Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group Leukemia 1995 9: 2042–2048
Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, Masi M, Tribalto M, Amadori S, Papa G . Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia Blood 1996 87: 1997–2004
Nussler V, Pelka-Fleischer R, Zwierzina H, Nerl C, Beckert B, Gieseler F, Diem H, Ledderose G, Gullis E, Sauer H, Wilmanns W . P-glycoprotein expression in patients with acute leukemia-clinical relevance Leukemia 1996 10 (Suppl. 3): S23–S31
Van den Heuvel-Eibrink MM, van der Holt B, te Boekhorst PAW, Pieters R, Schoester M, Lowenberg B, Sonneveld P . MDR-1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia Br J Haematol 1997 99: 76–83
Hunault M, Zhou D, Delmer A, Ramond S, Viguie F, Cadiou M, Oerrot JY, Levy V, Rio B, Cymbalista F, Zittoun R, Marie JP . Multidrug resistance gene expression in acute myeloid leukemia: major prognostic significance for in vivo drug resistance to induction treatment Ann Hematol 1997 74: 65–71
Del Poeta G, Venditti A, Aronica G, Stasi R, Cox MC, Buccosano F, Bruno A, Tamburini A, Suppo G, Simone MD, Epiceno AM, Del Moro B, Masi M, Papa G, Amadori S . P-glycoprotein expression in de novo acute myeloid leukemia Leuk Lymphoma 1997 27: 257–274
Willman CL . The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program Semin Hematol 1997 34 (4 Suppl. 5): 25–33
Borg AG, Burgess R, Green LM, Scheper RJ, Yin JA . Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival Br J Haematol 1998 103: 1083–1091
Zhou DC, Zittoun R, Marie JP . Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia Leukemia 1995 9: 1661–1666
Te Boekhorst PA, Lowenberg B, van Kapel J, Nooter K, Sonneveld P . Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia Leukemia 1995 9: 1025–1031
Filipits M, Suchomel RW, Zochbauer S, Brunner R, Lechner K, Pirker R . Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome Clin Cancer Res 1997 3: 1419–1425
Lohri A, van Hille B, Bacchi M, Fopp M, Joncourt F, Reuter J, Cerny T, Fey MF, Herrman R . Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK) Eur J Haematol 1997 59: 206–215
Hart SM, Ganeshaguru K, Scheper RJ, Prentice HG, Hoffbrand AV, Mehta AB . Expression of the human major vault protein LRP in acute myeloid leukemia Exp Hematol 1997 25: 1227–1232
Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL . Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study Blood 1997 89: 3323–3329
Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP . Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients Blood 1998 91: 4480–4488
Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP . Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia Blood 1999 94: 1046–1056
Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani G, Scheper RJ, Baccarani M . P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications Br J Haematol 1999 104: 328–335
Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, Van Waardenburg RC, Ruevekanp-Helmers MC, Floot BG, Schellens JH . Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line Cancer Res 1999 59: 4559–4563
Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD . A multidrug resistance transporter from human MCF-7 breast cancer cells (published erratum appears in Proc Natl Acad Sci USA 1999 Mar 2;96(5):2569) Proc Natl Acad Sci USA 1998 95: 15665–15670
Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA . Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines J Natl Cancer Inst 1999 91: 429–433
Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE . Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes Cancer Res 1999 59: 8–13
De Bruin M, Miyake K, Litman T, Robey R, Bates SE . Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR Cancer Lett 1999 146: 117–126
Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M . A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance Cancer Res 1998 58: 5337–5339
Ross DD, Karp JE, Chen TT, Doyle LA . Expression of breast cancer resistance protein in blast cells from patients with acute leukemia Blood 2000 96: 365–368
Ross DD . Novel mechanisms of drug resistance in leukemia Leukemia 2000 14: 467–473
Ross DD, Doyle LA, Schiffer CA, Lee EJ, Grant CE, Cole SP, Deeley RG, Yang W, Tong Y . Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients Leukemia 1996 10: 48–55
Van den Heuvel MM, Wiemer EAC, de Boevere MJ, van der Holt B, Vossebeld PJM, Pieters R, Sonneveld P . The role of MDR1 gene related clonal selection and P-gp function and expression in the development of AML towards relapsed/refractory disease Blood 2001 97: 3605–3611
Ino T, Miyazaki H, Isogai M, Nomura T, Tsuzuki M, Tsuruo T, Ezaki K, Hirano M . Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome Leukemia 1994 8: 1492–1497
Ito Y, Tanimoto M, Kumazawa T, Okumura M, Morishima Y, Ohno R, Saito H . Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells. Sequential analysis of 15 cases at initial presentation and relapsed stage Cancer 1989 63: 1534–1538
List AF . Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia Leukemia 1996 10: 937–942
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C . Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group Ann Intern Med 1985 103: 620–625
Mittelman F (ed). ISCN (1995). An International System for Human Cytogenetic Nomenclature Karger: Basel 1995
Hählen K, Bokkerink J, Van den Does-van den Berg A . Six months of intensive chemotherapy for childhood ANLL; preliminary results of the study ANLL87 of the DCSLG Haematol Blood Transf 1994 35: 734–735
Hählen K, Weening RS, Postma A, Bökkerink JPM, Kardos G, Van Weerden JF, Pieters R, Van den Does-van den Berg A . Results of DCLSG protocol ANLL94, BFM oriented intensive chemotherapy, followed by allogeneic or autologous bone marrow transplantation Med Pediatr Oncol 2000 35: 251 (121a)
Löwenberg B, van Putten WL, Touw IP, Delwel R, Santini V . Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia N Engl J Med 1993 328: 614–619
Meijerink JPP, Mandigers C, Vandelocht C, Tonnessen E, Goodsaid F, Raemakers J . A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR J Mol Diag 2001 3: 55–61
Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S . Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16 Cancer Res 1988 48: 1926–1929
Mechetner EB, Roninson IB . Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody Proc Natl Acad Sci USA 1992 89: 5824–5828
Chaudhary PM, Roninson IB . Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells Cell 1991 66: 85–94
Ludescher C, Thaler J, Drach D, Drach J, Spitaler M, Gattringer C, Huber H, Hofmann J . Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123 Br J Haematol 1992 82: 161–168
Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE . Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein Cancer Res 1986 46: 5125–5130
Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH . The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin Cancer Res 1999 59): 4237–4241
Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM . Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein Cancer Res 2000 60: 47–50
Croop JM, Tiller GE, Fletcher JA, Lux ML, Raab E, Goldenson D, Son D, Arciegas S, Wu RL . Isolation and characterization of a mammalian homolog of the Drosophila white gene Gene 1997 185: 77–85
Ewart GD, Howells AJ . ABC transporters involved in transport of eye pigment precursors in Drosophila melanogaster Methods Enzymol 1998 292: 213–224
Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL . Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study Blood 1999 94: 1086–1099
Den Ouden D, van den Heuvel M, Schoester M, van Rens G, Sonneveld P . In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells Leukemia 1996 10: 1930–1936
Van Loevezijn A, Allen JD, Schinkel AH, Koomen GJ . Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines Bioorg Med Chem Lett 2001 11: 29–32
Xu D, Arestrom I, Virtala R, Pisa P, Peterson C, Gruber A . High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone Br J Haematol 1999 106): 627–633
Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB . Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia Leukemia 1994 8: 2163–2168
Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH . Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia Blood 1995 85: 186–193
Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS . Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells Cancer Res 1994 54: 4676–4679
Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V . Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias Br J Haematol 1995 89: 356–363
Beck J, Handgretinger R, Klingebiel T, Dopfer R, Schaich M, Ehninger G, Niethammer D, Gekeler V . Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML Leukemia 1996 10: 426–433
List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS . Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia Blood 1996 87: 2464–2469
Musto P, Cascavilla N, Di Renzo N, Ladogana S, La Sala A, Melillo L, Nobile M, Matera R, Lombardi G, Carotenuto M . Clinical relevance of immunocytochemical detection of multidrug-resistance-associated P-glycoprotein in hematologic malignancies Tumori 1990 76: 353–399
Marie JP, Zittoun R, Sikic BI . Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity Blood 1991 78: 586–592
Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R . Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations Cancer Res 1996 56: 3010–3020
Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O . Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry Blood 1995 85: 2147–2153
Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M . Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia Cytometry 1994 17: 84–93
Michieli M, Giacca M, Fanin R, Damiani D, Geromin A, Baccarani M . Mdr-1 gene amplification in acute lymphoblastic leukaemia prior to antileukaemic treatment Br J Haematol 1991 78: 288–289
Wood P, Burgess R, MacGregor A, Yin JA . P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival Br J Haematol 1994 87: 509–514
Sato H, Preisler H, Day R, Raza A, Larson R, Browman G, Goldberg J, Vogler R, Grunwald H, Gottlieb A . MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia Br J Haematol 1990 75: 340–345
Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R . Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression Leukemia 1993 7: 825–831